Shionogi Sets Up In Europe, To Develop Pipeline Before The "Crestor Cliff"
This article was originally published in PharmAsia News
Executive Summary
Anticipating the loss of royalties from Crestor in the next five years, Japanese innovator Shionogi continues its globalization process with a U.K. headquarters to pursue development of its late-stage research pipeline in Europe.
You may also be interested in...
Shionogi To Switch Europe HQ Out Of London Over Brexit
The drug maker looks set to join fellow Japanese firms Sony and Panasonic in moving its European legal base out of the UK as the uncertainties surrounding Brexit show little sign of being resolved.
Profile Of Viiv’s Unboosted Dolutegravir Emerges With First Phase III Results
Viiv Healthcare/Shionogi’s once-daily, unboosted integrase inhibitor dolutegravir is efficacious and well-tolerated in the first of four Phase III HIV trials to report, a study of treatment-naïve patients. Drug poses a competitive threat to Merck’s blockbuster Isentress and Gilead’s elvitegravir, part of the four-in-one “Quad” pill.
Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning
TOKYO - Shionogi & Co. Ltd. will expand its operations in China with the acquisition of C&O Pharmaceutical Technology Ltd., following through on a promise from its midterm plan to push into Asia to mitigate the 2016 patent loss of blockbuster Crestor (rosuvastatin)